6909-93-9 Usage
General Description
2,5-Diamino-4-Picoline is a chemical compound characterized by the presence of two amino groups (NH2) and a pyridine ring in its structure, signifying its classification as an aromatic amine. This organic compound is typically used in the field of chemistry, particularly in the synthesis of other chemical substances or in research settings, given its role as a useful intermediate. It's crucial to handle it with care as it's likely harmful if swallowed or comes into contact with skin, and it might cause serious eye irritation. It's characterized by the CAS registry number 26264-02-2, however, detailed information regarding its physical and chemical properties, such as its molecular weight, boiling or melting points, is often not readily available.
Check Digit Verification of cas no
The CAS Registry Mumber 6909-93-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,9,0 and 9 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 6909-93:
(6*6)+(5*9)+(4*0)+(3*9)+(2*9)+(1*3)=129
129 % 10 = 9
So 6909-93-9 is a valid CAS Registry Number.
InChI:InChI=1/C6H9N3/c1-4-2-6(8)9-3-5(4)7/h2-3H,7H2,1H3,(H2,8,9)/p+1
6909-93-9Relevant articles and documents
INHIBITORS OF HEPATITIS C VIRUS REPLICATION
-
Paragraph 0519-0520, (2019/05/15)
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Non-amidine containing protease inhibitors
-
Page 7, (2010/02/05)
The present invention provides novel compounds of the Formula (I) its prodrug forms, or pharmaceutically acceptable salts thereof. Preferred (I) compounds of the present invention comprise a pyrrolo pyridinyl, pyrrolo pyrimidinyl or indole nucleus. The compounds of this invention are inhibitors of Factor Xa (FXa), Factor VIIa (FVIIa) and/or serine proteases, Urokinase (uPA), and have utility as anti-coagulants for the treatment or prevention of thromboembolic disorders in mammals and as anticancer agents.
Xi:Irritant;
